EUCTR2006-005450-71-DE进行中（未招募）不适用
INTRAVITREAL RANIBIZUMAB THERAPY FOR MACULA EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (RAVO) - RAVO
Augenklinik der LMU München0 个研究点目标入组 60 人开始时间: 2007年1月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who at baseline
- •have a BCVA letter score in the study eye between finger count5 (1m distance) and 65 (4m distance) (approximately 20/3205/400 5/200 to 20/40 Snellen equivalent and 1,846 – 0,34 logMar) using an ETDRS chart measured at 4 meters or at 1 m.
- •have cystoid macular edema secondary to CRVO (ischemic or non ischemic - defined by fluorescein angiography) of =300µm.. In case of development of neovascularistation laser photocoagulation will be performed as recommended by the Central Retinal Vein Occlusion Study
- •maximum history of symptoms: 6 months8 weeks
- •will be willing to return for all scheduled visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A condition that in the opinion of the investigator would preclude a patient’s participation in the study, e.g., unstable medical status including blood pressure. Patients with hypertension for whom a change in antihypertensive treatment was initiated within 2 months preceding Day 1 should not be enrolled unless blood pressure is maintained for at least 1 month below 150/95 mm Hg by antihypertensive treatment.
- •History of systemic (e.g., oral, intravenously, intramuscular, epidural, bursal) corticosteroids within 2 months prior to randomization or topical, rectal, or inhaled corticosteroids in current use more than 2 times per week.
- •significant ischaemic heart disease (history of myocardial infarction less than 6 months ago, unstable angina, ischaemic ECG)
- •history of heart disease (NYHA grade III-VI)
- •history of cerebrovascular event less than 6 months ago
- •grossly abnormal urea and electrolytes
- •history of significant pulmonary disease
- •haematocrit (PCV) below 0,37
- •Concurrent Ocular Conditions
- •Vitreomacular traction or epiretinal membrane in the study eye evident by slit lamp examination or by OCT
- •Active intraocular inflammation (grade trace or above) in either eye
- •Any active infection involving ocular adnexa including infectious conjunctivitis, keratitis, scleritis, endophthalmitis, as well as idiopathic or autoimmune-associated uveitis in either eye
- •Structural damage to the center of the macula in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), or organized hard exudate plaques
- •Ocular disorders in the study eye that may confound interpretation of study results, including retinal detachment, macular hole, or choroidal neovascularization of any cause (e.g., AMD, ocular histoplasmosis, or pathologic myopia)
- •Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the 28-week12-month study period
- •History of uncontrolled glaucoma (defined as intraocular pressure =25 mm Hg despite treatment with anti-glaucoma medication) or low tension glaucoma in the study eye
- •History of glaucoma filtration surgery, corneal transplant surgery in the study eye
- •Ocular conditions that require chronic concomitant therapy with systemic or topical ocular corticosteroids. Chronic concomitant therapy is defined as multiple doses taken daily for three or more consecutive days at any time within 6 months prior to screening or during the course of the study
- •Systemic Conditions
- •Blood pressure: Systolic = 150 mmHg and/or Diastolic = 95 mmHg
- •oIf blood pressure is brought and maintained for at least 1 month below 150/95 mm Hg by antihypertensive treatment, patient can become eligible
- •History of chronic renal failure requiring dialysis or kidney transplant
- •Pre-menopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization; use of oral contraceptives; barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel; an IUD; or contraceptive hormone implant or patch
- •Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/ml)
- •Current treatment for active systemic infection
研究者
相似试验
进行中（未招募）
1 期
Rituximab and Bendamustine in very old patients or old and medically unfit patients with CD20-positive B-cell lymphomaVery elderly or elderly medically non fit patients with aggressive CD20 positive B-cell lymphomaMedDRA version: 20.0Level: PTClassification code 10003899Term: B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024004-98-DEniversity Medicine Göttingen Dept. Hematology and Oncology68
进行中（未招募）
1 期
The use of Ranibizumab (Lucentis ®) for the treatment of corneal neovascularisation - Management and control of corneal neovascularisation using LucentisCorneal neovesselsEUCTR2010-018673-37-GBniversity of Nottingham6
尚未招募
不适用
The switching therapy with Ranibizumab for Exudative Age-related Macular Degeneration resistant to AfliberceptJPRN-UMIN000012724Department of Ophthalmology, Kagawa university faculty of medicine30
进行中（未招募）
1 期
Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) TrialEUCTR2017-003243-37-GBMUST Coordinating Centre, John Hopkins Bloomberg School of Public Health240
进行中（未招募）
1 期
Research study to investiagte if Ranibizumab treatment is safe and effective in patients with Ocular melanoma (eye tumour) before surgery.veal Melanoma (requiring enucleation)MedDRA version: 14.0 Level: PT Classification code 10025654 Term: Malignant melanoma of sites other than skin System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000961-10-GBRoyal Liverpool and Broadgreen University Hospitals Trust7